Daneng Li

GI Medical Oncologist @CityofHope. Hepatobiliary & NET Cancers

[ASCO @ASCO]

As the sun sets in San Francisco & #GI26 comes to a close, we reflect w/ gratitude on the 3 days we spent w/ all of you in person & online. Three full days of learning & connecting, making progress on treatments and care for patients w/ GI cancers. #gicsm
https://t.co/7zmchdw5JQ

[Daneng Li @DanengLi]

It was wonderful doing this with amazing colleagues @ASCO #GI26. Safe travels to all and look forward to more amazing science later this year @ASCO.

[ASCO @ASCO]

It was wonderful meeting many of our #GI26 Featured Voices in person! A huge ‘thank you’ to ALL of you for lending your time & expertise to help digest symposium findings and provide key takeaways. We couldn’t do it without you!

[Pranati Shah @pshah_88]

#ASCOGI26 Day 2 ✌️ presenting a meta-analysis on ctDNA as a marker in patients with colorectal cancer with liver metastasis. Thank you for the amazing mentorship from @cityofhope @gagan_brar24 @DaniCastilloMD @montypal

[Daneng Li @DanengLi]

Agree with @jgong15. Good to see studies and investigators doing the right thing and reevaluating continuation of studies when new data becomes available and standards of care changes. Putting patients first is key. @ASCO #GI26

[Jun Gong @jgong15]

Dr. Max rand PhIII COMMIT @NRGonc of #1L #atezo +/- FOLFOX in #MSI-H #mCRC ➡️ improved PFS median 24.5 vs 5.3 mos, immature OS, ORR 36.1 vs 18.9% FOLFOX-atezo vs atezo, respectively. Note, study closed after CM-8HW after 102 pts accrued (right thing to do)

@OncoAlert #GI26

[Daneng Li @DanengLi]

Impressive follow up results from Breakwater showing promising OS trend with combination therapy for an aggressive CRC population. How to further improve giving already at quadruple therapy combination. Novel mechanisms of action needed for the future. @ASCO #GI26

[Daneng Li @DanengLi]

Very interesting findings presented @ASCO #GI26. Could GLP1 have different effects on different GI cancers?Some preclinical data in NETs have shown some possibility of increased risk. Definitely an area of interest to watch out for moving forward.

[ASCO @ASCO]

Promising news from #GI26: Popular weight-loss drugs may have the added benefit of reducing #ColorectalCancer risk.

Learn more: https://t.co/Vk6XUGXUr6
#GLP1RA

[Pashtoon Kasi MD, MS @pashtoonkasi]

#GI26 Provocative but insightful recommendations on how to select patients for LIVER #Transplant for patients with unresectable liver metastases.

Liver transplant is here to stay. Early selection is of value. But dogmas e.g. no BRAFV600E or N2 need to be challenged.
@OncoAlert

[Gagan Brar @gagan_brar24]

Next generation of stellar GI oncologists discussing the impact of ctdna in CRLM #GI26 @ASCO @pshah_88 @DaniCastilloMD @DanengLi @pashtoonkasi @cityofhope

[Pierre Gholam @pgholam]

Standing room only for this @ASCO #GI26 session on optimizing management of persons with #HCC and decomp #cirrhosis

We spoke about achieving good cancer outcomes with bad livers with co panelists Drs. @BeauToskichMD Stephen Lam Chan and Ana Gleisner.

#livertwitter

[Natasha @thehemeoncdoc]

Great work by one of our surgical colleagues looking at PIN1 expression and PDAC OS. The results may surprise you… @ASCO #GI26 @DanengLi @DaniCastilloMD @gagan_brar24

[Gagan Brar @gagan_brar24]

Excellent summary of two important #HCC abstracts at #GI26 by my mentor and colleague Tim Greten @ASCO @DanengLi @DaniCastilloMD

[Daneng Li @DanengLi]

ABC-HCC in intermediate #HCC showing early time to treatment failure benefit with atezo bev versus TACE. If OS can be shown to be positive, a change of strategy from upfront liver directed therapy to saving it at progression to systemic therapy may be preferred. #GI26 @ASCO

[Daneng Li @DanengLi]

keynote 937 negative study for adjuvant #HCC in line with prior results from IMbrave 050. Unfortunately, still lack of positive #HCC trials. Novel strategies needed since given uniqueness of HCC adjuvant population and underlying cirrhosis. #GI26 @ASCO

[Daneng Li @DanengLi]

Impressive waterfall plot for lirafugratinib 46.5% ORR in FGFR2 positive BTC including 22% in previously treated FGFR2 targeted therapy pts. Trade offs of toxicity with lira compared to other FGFR2 agents. Sequencing studies now needed in the field. #GI26 @ASCO

[Natasha @thehemeoncdoc]

Come talk to me about MSI-H gastric cancer! @DaniCastilloMD @DanengLi
@ASCO #GI26

[Natasha @thehemeoncdoc]

Great contrasting presentations by Dr. Lucjan Wyrwicz and Dr. Naruhiko Ikoma to help figure out the best way to approach resectable MSI-H gastric cancer
@ASCO #GI26 @DanengLi @DaniCastilloMD

[Daneng Li @DanengLi]

Great discussion by Dr. Daniel Lin. For Herizon study, agree with outdated comparator arm is big limitation so big question now is who would actually use it if our current SOC is not truly represented. @ASCO #GI26

[Dani Castillo @DaniCastilloMD]

ASCO #GI26 Valuable studies emphasize the value of incorporating XRT into the perioperative setting. Appropriate patient selection is crucial, considering tumor biology and QoL, Engaging in MDT discussions is essential, with the overarching goal of improving OS while ensuring that QoL is not compromised @gagan_brar24 @SteveMaronMD @jgong15 @daneng li

[Daneng Li @DanengLi]

Looking forward to providing perspectives on all the amazing work to be shared at #GI26 @ASCO. Excited to work with such a wonderful group of colleagues, researchers, and advocates.

[ASCO @ASCO]

We’re excited to announce our Featured Voices for the 2026 ASCO Gastrointestinal Cancers Symposium! Get their expert perspectives, find out which abstracts and sessions they’re most excited about, and join the conversation with the official meeting hashtag, #GI26.

[Daneng Li @DanengLi]

Thanks for highlighting our work led by @DaniCastilloMD @cityofhope @CityofHopeSurg

[Erman Akkus @Erman_Akkus]

Distinct clinicopathological and survival profiles of CLDN18.2 and PD-L1 expression in advanced gastric cancer and gastroesophageal junction adenocarcinoma - ESMO Gastrointestinal Oncology https://t.co/9rGfBJifYy